Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The biological mechanisms underlying early- and advanced-stage epithelial ovarian cancers (EOCs) are still poorly understood. This study explored kinase-driven metabolic signalling in early and advanced EOCs, and its role in tumour progression and response to carboplatin-paclitaxel treatment.
Methods: Tumour epithelia were isolated from two independent sets of primary EOC (n=72 and 30 for the discovery and the validation sets, respectively) via laser capture microdissection. Reverse phase protein microarrays were used to broadly profile the kinase-driven metabolic signalling of EOC with particular emphasis on the LBK1-AMPK and AKT-mTOR axes. Signalling activation was compared between early and advanced lesions, and carboplatin-paclitaxel-sensitive and -resistant tumours.
Results: Advanced EOCs were characterised by a heterogeneous kinase-driven metabolic signature and decreased phosphorylation of the AMPK-AKT-mTOR axis compared to early EOC (P<0.05 for AMPKα T172, AMPKα1 S485, AMPKβ1 S108, AKT S473 and T308, mTOR S2448, p70S6 S371, 4EBP1 S65, GSK-3 α/β S21/9, FOXO1 T24/FOXO3 T32, and FOXO1 S256). Advanced tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin-paclitaxel resistance.
Conclusions: If validated in a larger cohort of patients, the decreased AMPK-AKT-mTOR activation and phosphorylation of FOXO1 T24/FOXO3 T32 may help identify carboplatin-paclitaxel-resistant EOC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558684 | PMC |
| http://dx.doi.org/10.1038/bjc.2017.195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.
J Enzyme Inhib Med Chem
December 2025
Department and Chair of Organic Chemistry, Poznan University of Medical Sciences, Poznan, Poland.
FDA-approved kinase inhibitors represent a rapidly growing class of targeted therapies with proven clinical success in oncology. However, their occupancy-driven mode of action is often associated with resistance, off-target effects, and incomplete inhibition. Proteolysis-Targeting Chimaeras (PROTACs) offer a compelling alternative by promoting complete degradation of oncogenic kinases, thereby enhancing selectivity and resistance reduction.
View Article and Find Full Text PDFBrain-derived neurotrophic factor levels and oxidative stress in autism: evidence from children and a mouse model.
J Psychiatry Neurosci
July 2025
From the Hainan Women and Children's Medical Center, Hainan Medical University (Zhang, Fu, M. Wang, Feng, H. Wang, H. Li, L. Li, Yao); Department of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen China (Liu, Zeng)
Background: Brain-derived neurotrophic factor (BDNF) is a key factor in neurodevelopment of autism spectrum disorder (ASD), yet the variability of peripheral BDNF levels in ASD remains debated. We sought to investigate the relationship between circulating oxidative stress and peripheral BDNF in children with ASD.
Methods: We analyzed plasma BDNF levels and redox status in both plasma and peripheral blood mononuclear cells (PBMCs) among children with ASD and typically developing (TD) children aged 2-5 years.
Discovery of potent anti-idiopathic pulmonary fibrosis (IPF) agents based on an o-aminopyridinyl alkynyl scaffold.
Eur J Med Chem
September 2025
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai, 201203, China. Electronic address:
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with high mortality and limited treatment options. Targeting multiple kinase-driven pathological processes offers a promising strategy. Using epithelial-mesenchymal transition (EMT) phenotypic screening, we optimized a series of o-aminopyridinyl alkynyl compounds derived from CSF-1R relatively selective inhibitor, compound 1, through a structure-activity relationship (SAR) study, integrating liver and kidney cytotoxicity evaluations.
View Article and Find Full Text PDFPhiladelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a molecularly distinct tyrosine kinase-driven cancer that has a high relapse rate and poor response toward combinatorial chemotherapy. Tyrosine kinase inhibitors (TKI) in the clinic improve the survival of patients with Ph-like ALL. Engineered antibody and cell-based immunotherapies can advance treatment for this genetic subtype of ALL.
View Article and Find Full Text PDFA metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer.
Nat Commun
March 2025
Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker Enfants-Malades, Université Paris Cité, Paris, France.
Article Synopsis
- The activation of the PI3K pathway is a common feature in aggressive tumors that helps them adapt and resist chemotherapy.
- Researchers are investigating the metabolic weaknesses of T-cell acute lymphoblastic leukemia (T-ALL), a severe type of cancer influenced by PI3K changes.
- Combining glutamine degradation with mTOR inhibition shows promising effectiveness against both solid tumors and blood cancers driven by PI3K, suggesting a new treatment approach.